ArticleLung cancer (Amsterdam, Netherlands)2024

Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer.

Jessica R Bauman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.